Ratings Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Real-time Estimate Cboe BZX Other stock markets 12:10:27 2024-05-03 pm EDT			5-day change	1st Jan Change
35.84 ^USD	-1.17%		+6.59%	+66.22%

May. 02	Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target	MT
Apr. 19	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
SPYRE THERAPEUTICS, INC.	+66.22%	1.46B	C-
VERTEX PHARMACEUTICALS INCORPORATED	-1.63%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+7.69%	101B	B+
ARGENX SE	+4.40%	23.07B	B
BIONTECH SE	-11.86%	22.23B	B+
GENMAB A/S	-4.36%	18.05B	A-
WUXI APPTEC CO., LTD.	-39.98%	17.18B	A-
BEIGENE, LTD.	-10.67%	16.94B	B
NEUROCRINE BIOSCIENCES, INC.	+6.54%	14.07B	C+
SAREPTA THERAPEUTICS, INC.	+38.05%	12.35B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes